Study of the efficacy and safety of gemtuzumab ozogamicin treatment intervention with measurable residual disease as an index for AYA/adult acute myeloid leukemia with t(8;21) and inv(16)

Toshihiro Miyamoto0 个研究点目标入组 117 人开始时间: 2020年11月13日最近更新: 2024年1月22日

试验速览

暂无简介。

•1.Newly diagnosed as core-binding factor acute myelogenous leukemia (CBF-AML)
•2.Quantitative detection of RUNX1-RUNX1T1 or CBFB-MYH11 mRNA at presentation
•3.Patients who are planned to undergo or are ongoing the standard '7+3' AML indcution chemotherapy
•4.Patients who have not received consolidation chemotherapy
•5. AML bast cells express CD33 on cell surface
•6.ECOG performance status score 0,1,2
•7.Having sufficient function of liver, kidney, lung, and heart
•8.Having ablitity to concent with chemotherapy for AML in written forms
•9.For patients younger than 20 years, consent of the person in charge must be obtained along with individual

•1.Myelodysplastic syndrome-derived or atypical AML
•2.Patients who have had Down syndrome or congenital disease
•3.Patients with a history of hematological disorders prior to enrollment into this study
•4.Patients in whom measurable residula disease (MRD) anayses have been done after induction therapy
•5.Patients who have been treated with gemtuzumab ozogamicin (GO) during induction chemotherapy
•6.Patinets who have other active cancer
•7.Patients with a history of myocardial infarction within a year
•8.Diabetic patients with poor control
•9.Patients with infectious complications with poor control
•10.Patients with liver cirrhosis
•11.Patients with a history of renal insufficiency
•12.Patients with deep venous thrombosis to be treated
•13.Patients who have mental disorders
•14.Pregnant women
•15.HBs antigen positive, or HCV antibody positive

发起方

Toshihiro Miyamoto